Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A new site revision label Revision: v3.4.2 appears and a prior government-funding status notice is removed. These are general site-wide UI updates and do not affect the study details or eligibility criteria.
    Difference
    0.4%
    Check dated 2026-02-11T05:34:37.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A system notice about government funding lapse and NIH Clinical Center status was added, and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T05:16:53.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added glossary toggle to the study page and updated metadata labels (including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'), with slight wording/capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T03:45:00.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:42:32.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations now include Massachusetts; HHS Vulnerability Disclosure and Massachusetts Locations sections were removed.
    Difference
    0.2%
    Check dated 2025-12-23T10:11:36.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision: v3.3.2 is now shown, replacing the previous v3.3.1. No other study content or functionality appears to be affected.
    Difference
    0.1%
    Check dated 2025-12-01T17:46:49.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.